Cardiogenic Shock clinical trials

Explore recruiting cardiogenic shock clinical trials.

Recruiting cardiogenic shock studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cardiogenic Shock trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock from Acute Myocardial Infarction - NORshock

Netherlands, Denmark, Slovenia, Germany, Sweden, Belgium +3 more

Therapeutic use (Phase IV) EU CTIS Study details

Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock. LevoHeartShock

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effect at 3 months of early empagliflozin initiation in cardiogenic shock patients on mortality, rehospitalization, left ventricular ejection fraction and renal function. A randomized multicentric open trial. (EMPASHOCK)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stage C (SEISMiC-C)

Poland, Czechia, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized Embedded Multifactorial Adaptive Platform in ExtraCorporeal Membrane Oxygenation (REMAP ECMO) - Beta receptor modulation trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Effects of Levosimendan in patients being weaned from venoarterial extracorporal membrane oxygenation. A randomized controlled investigator driven phase II trial

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Cardiogenic Shock trials by city

Cardiogenic Shock in Toronto Cardiogenic Shock in Vancouver Cardiogenic Shock in Montreal Cardiogenic Shock in Calgary Cardiogenic Shock in Edmonton Cardiogenic Shock in Ottawa Cardiogenic Shock in Winnipeg Cardiogenic Shock in Quebec City Cardiogenic Shock in Hamilton Cardiogenic Shock in Kitchener Cardiogenic Shock in London Cardiogenic Shock in Halifax Cardiogenic Shock in New York Cardiogenic Shock in Los Angeles Cardiogenic Shock in Chicago Cardiogenic Shock in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease